Clinical Trials Sponsored by Legacy Healthcare SA

Total 50 results

Legacy Healthcare SA

Completed

Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN) (ELAN)

Alopecia

Switzerland
Legacy Healthcare SA

Completed

Efficacy and Safety of LH-8 in Paediatric Alopecia Areata (AA)

Alopecia Areata | Pediatric Disorder

France, Germany, Bulgaria
Samsung Medical Center
Legacy Healthcare Services

Completed

A 6-month Post-interventional Follow-up Extension of VOLUME Study (VOLUME-2) (VOLUME2)

Alopecia | Chemotherapy Effects

Korea, Republic of
Samsung Medical Center
Legacy Healthcare Services

Completed

EValuation of the Impact of a TOpical Lotion on Permanent Chemotherapy Induced Hair Disorders in Cancer Survivors (VOLUME)

Alopecia

Korea, Republic of
Helsinn Healthcare SA

Active, not recruiting

Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk) (CINV)

Chemotherapy-induced Nausea and Vomiting

Spain, Germany, Switzerland, China, Czechia, United Kingdom, Greece
Helsinn Healthcare SA

Completed

Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
Helsinn Healthcare SA

Completed

PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting (CINV)

Chemotherapy-induced Nausea and Vomiting (CINV)

United States, Russian Federation, Serbia, Ukraine
Helsinn Healthcare SA

Completed

Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking Subjects

Healthy Volunteers | Non-smokers

United States
Helsinn Healthcare SA

Completed

Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients

Chemotherapy-Induced Nausea and Vomiting

United States, Argentina, Poland, Peru, Russian Federation, Germany, Austria, Chile, Ukraine, Bulgaria, Czech Republic, Estonia, France, Hungary, Romania, Serbia
Helsinn Healthcare SA

Completed

Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients

Postoperative Nausea and Vomiting

United States, Czech Republic, Argentina, Hungary, Poland, Puerto Rico, Russian Federation, Ukraine
Helsinn Healthcare SA

Terminated

XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors

Biliary Tract Cancer

United States, Spain, Canada, France, Germany, Hungary, Italy, Belgium, Poland, Russian Federation, United Kingdom
Helsinn Healthcare SA

Terminated

Effects of Somnage® in the Management on Sleep and Mood in Cancer Patients

Breast Cancer | Lung Cancer | Colon Cancer

Italy
Helsinn Healthcare SA

Completed

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA (MEI-005)

Myelodysplastic Syndrome | MDS

United States
Helsinn Healthcare SA

Withdrawn

Evaluation of the Effects of a Mixture of Amino Acids (Amixea) on Lean Body Mass and Muscle Strengh of Patients With Unresectable Advanced Non-small Cell Lung Cancer

Cancer Patients With Cachexia

Australia
Helsinn Healthcare SA

Completed

Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea

Diarrhea

Russian Federation, Bulgaria, Hungary, Romania
Helsinn Healthcare SA

Completed

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer | Cachexia; Cancer

United States, Russian Federation, Bulgaria, Hungary, Italy, Romania, Serbia
Helsinn Healthcare SA

Completed

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer | Cachexia; Cancer

United States, Croatia, Australia, Belgium, Russian Federation, Poland, Romania, Ukraine
Helsinn Healthcare SA

Terminated

A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Helsinn Healthcare SA

Completed

Monocenter, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Xonrid®

Quality of Life | Radiodermatitis

Italy
Helsinn Healthcare SA

Completed

Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Helsinn Healthcare SA

Completed

Efficacy Study of Ginger (Zingiber Officinale) Extract "Ginpax" to Manage Nausea in Cancer Patients Receiving High Emetogenic Treatments and Standard Anti-emetogenic Therapy

Cancer | Nausea | Vomiting

Italy
Helsinn Healthcare SA

Completed

Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients

Postoperative Nausea and Vomiting

Russian Federation, Ukraine
Helsinn Healthcare SA
Parexel

Completed

An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting

Chemotherapy-Induced Nausea and Vomiting

Italy, United States, Argentina, Bulgaria, Croatia, Germany, Hungary, India, Poland, Romania, Russian Federation, Ukraine
Helsinn Healthcare SA
Parexel

Completed

An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

Chemotherapy-Induced Nausea and Vomiting

United States, Germany, Italy, Argentina, Bulgaria, Croatia, Hungary, India, Poland, Romania, Russian Federation, Ukraine, Mexico, Brazil, Belarus
Helsinn Healthcare SA
Parexel

Completed

A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

Chemotherapy-Induced Nausea and Vomiting

Serbia, United States, Ukraine, Germany, Poland, Czech Republic, Bulgaria, Hungary, India, Russian Federation
Helsinn Healthcare SA
Celerion

Completed

Study to Evaluate the Food Effect of Single-dose Bioavailability of Pracinostat in Healthy Adult Subjects (HVFE)

Healthy Volunteers | Non-smokers | Moderate to Heavy Smokers

United States
Helsinn Healthcare SA
PSI CRO

Completed

A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting

Chemotherapy-Induced Nausea and Vomiting

Serbia, United States, Israel, Germany, Czechia, Spain, Croatia, Ukraine, South Africa, Austria, Italy, Poland
Helsinn Healthcare SA
Clinipace Worldwide

Terminated

An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, Spain, Australia, Taiwan, France, Italy, United Kingdom, Korea, Republic of, Argentina, Austria, Brazil, Czechia, Germany, Hungary, Poland, Romania
Eisai Inc.
Helsinn Healthcare SA

Completed

Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.

Multiple Myeloma

United States
Helsinn Healthcare SA
Latis S.r.l.

Terminated

Effects of Aqualief® in Patients With Xerostomia as Consequence of Radiotherapy for Head and Neck Cancer

Xerostomia | Mouth Dryness | Hyposalivation | Asialia

Italy
Helsinn Healthcare SA
Quotient Sciences

Completed

A Study In Healthy Male Volunteers Designed To Investigate How A Radiolabelled Medicine Is Broken Down And Removed From The Body

Healthy Subjects

United Kingdom
Helsinn Healthcare SA
PSI CRO

Completed

An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting

Chemotherapy-Induced Nausea and Vomiting

Georgia, Russian Federation, Romania, Hungary, Belarus, Bosnia and Herzegovina, Bulgaria, Greece, Lithuania
Amazentis SA
Mprex Healthcare Pvt. Ltd.

Not yet recruiting

Bioavailability of Three Mitopure Formulations

Healthy Adults

India
Helsinn Healthcare SA
ICON Clinical Research

Recruiting

Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities ((MARGARET))

RET-altered Solid Tumors | RET-altered Non Small Cell Lung Cancer

United States, Japan
QED Therapeutics, Inc.
Helsinn Healthcare SA

Terminated

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

FGFR2 Gene Mutation | Advanced Cholangiocarcinoma

United States, Belgium, Germany, Italy, Korea, Republic of, Russian Federation, Singapore, Spain, Taiwan, Thailand, United Kingdom
Simon Williamson Clinic
Helsinn Healthcare SA

Recruiting

Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

Chemotherapy Induced Nausea and Vomiting

United States
QED Therapeutics, Inc.
Helsinn Healthcare SA

Terminated

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF302)

Upper Tract Urothelial Carcinomas | Urothelial Bladder Cancer

United States, France, Canada, Spain, Italy, Belgium, Germany, Netherlands, United Kingdom, Bulgaria, Greece
Helsinn Healthcare SA
Chiltern International Inc.

Completed

Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID)

Drug and/or Toxin-induced Diarrhea

Ukraine, Germany, Poland, Russian Federation, Belarus, Bulgaria, Hungary, Czechia
QED Therapeutics, Inc.
Helsinn Healthcare SA

Terminated

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

FGFR2 Gene Mutation | Advanced Cholangiocarcinoma

Korea, Republic of, United States, Belgium, Spain, Taiwan, China, United Kingdom, France, Canada, Germany, Thailand, Italy, Portugal, Australia, Puerto Rico
Odense University Hospital
Helsinn Healthcare SA

Completed

Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin (GAND-emesis)

Genital Neoplasms, Female | Nausea | Vomiting

Norway, Denmark, Germany, Australia
Lahey Clinic
Helsinn Healthcare SA; Quartesian LLC

Recruiting

Anamorelin Study for Advanced Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
M.D. Anderson Cancer Center
Helsinn Healthcare SA

Withdrawn

Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

Cholangiocarcinoma | Liver Cancer

United States
Helsinn Healthcare SA
Labcorp Drug Development Inc

Withdrawn

Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations (NEWEL)

Advanced Solid Tumor | CNS Tumor | Recurrent WHO Grade II Glioma

United States, Canada, Germany
M.D. Anderson Cancer Center
Helsinn Healthcare SA

Completed

Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)

Myeloproliferative Diseases

United States
Christina Ruhlmann
Helsinn Healthcare SA

Recruiting

Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin

Cervical Cancer | Chemotherapy-induced Nausea and Vomiting | Adverse Event

Denmark
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Helsinn Healthcare SA

Completed

Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer

Nausea | Vomiting | Malignant Neoplasm

United States
Helsinn Healthcare SA
The Physicians' Services Incorporated Foundation; George Clinical Pty Ltd

Completed

A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

Chemotherapy-induced Nausea and Vomiting

United States, Georgia
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
Merck Hellas sa., Greece, an affiliate of Merck KGaA, Darmstadt, Germany

Active, not recruiting

Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)

Multiple Sclerosis

Greece, Switzerland, Norway, Italy, Poland, Portugal
Fenway Community Health
Patient-Centered Outcomes Research Institute; Kaiser Permanente; Howard Brown... and other collaborators

Completed

Comparative Effectiveness Research to Improve the Health of Sexual and Gender Minority Patients Through Cultural Competence and Skill Training of Community Health Center Providers and Non-clinical Staff (PCORI-SOGI)

Education | Gender Identity | Sexual Orientation | LGBT Health | Cultural Competency

United States
Beth Israel Deaconess Medical Center
Medical University of South Carolina; Johns Hopkins University; University Health... and other collaborators

Recruiting

Statins In Intracerbral Hemorrhage (SATURN)

Intracerebral Hemorrhage

United States

Clinical Trials Sponsored by Legacy Healthcare SA

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations